|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CNPY2 |
Gene summary for CNPY2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CNPY2 | Gene ID | 10330 |
| Gene name | canopy FGF signaling regulator 2 | |
| Gene Alias | HP10390 | |
| Cytomap | 12q13.3 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q9Y2B0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10330 | CNPY2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 9.84e-06 | 1.54e-01 | 0.0155 |
| 10330 | CNPY2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 8.42e-05 | 1.62e-01 | -0.1808 |
| 10330 | CNPY2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.23e-05 | 2.32e-01 | -0.0811 |
| 10330 | CNPY2 | HTA11_78_2000001011 | Human | Colorectum | AD | 5.53e-03 | 1.14e-01 | -0.1088 |
| 10330 | CNPY2 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.93e-13 | 2.74e-01 | -0.1954 |
| 10330 | CNPY2 | HTA11_411_2000001011 | Human | Colorectum | SER | 4.01e-04 | 4.03e-01 | -0.2602 |
| 10330 | CNPY2 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.90e-02 | 2.76e-01 | -0.2196 |
| 10330 | CNPY2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.22e-02 | 1.46e-01 | -0.1207 |
| 10330 | CNPY2 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.83e-15 | 3.16e-01 | -0.1464 |
| 10330 | CNPY2 | HTA11_866_2000001011 | Human | Colorectum | AD | 6.35e-15 | 3.01e-01 | -0.1001 |
| 10330 | CNPY2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.87e-19 | 4.36e-01 | -0.059 |
| 10330 | CNPY2 | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.72e-05 | 3.56e-01 | -0.1706 |
| 10330 | CNPY2 | HTA11_546_2000001011 | Human | Colorectum | AD | 4.83e-05 | 2.15e-01 | -0.0842 |
| 10330 | CNPY2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.96e-03 | 1.98e-01 | -0.0179 |
| 10330 | CNPY2 | HTA11_866_3004761011 | Human | Colorectum | AD | 7.69e-23 | 4.39e-01 | 0.096 |
| 10330 | CNPY2 | HTA11_4255_2000001011 | Human | Colorectum | SER | 3.03e-06 | 3.08e-01 | 0.0446 |
| 10330 | CNPY2 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.95e-07 | 3.27e-01 | 0.0528 |
| 10330 | CNPY2 | HTA11_7663_2000001011 | Human | Colorectum | SER | 7.76e-08 | 3.83e-01 | 0.0131 |
| 10330 | CNPY2 | HTA11_10623_2000001011 | Human | Colorectum | AD | 3.04e-05 | 2.63e-01 | -0.0177 |
| 10330 | CNPY2 | HTA11_6801_2000001011 | Human | Colorectum | SER | 1.64e-05 | 3.00e-01 | 0.0171 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CNPY2 | SNV | Missense_Mutation | c.76N>G | p.Leu26Val | p.L26V | Q9Y2B0 | protein_coding | tolerated(0.19) | benign(0.022) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CNPY2 | SNV | Missense_Mutation | c.305N>A | p.Arg102His | p.R102H | Q9Y2B0 | protein_coding | tolerated(0.13) | probably_damaging(0.976) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| CNPY2 | SNV | Missense_Mutation | c.76C>G | p.Leu26Val | p.L26V | Q9Y2B0 | protein_coding | tolerated(0.19) | benign(0.022) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| CNPY2 | insertion | Frame_Shift_Ins | novel | c.389_390insGCATGATCATAACTCATTGCAGCCTCTAACTC | p.Ser130ArgfsTer74 | p.S130Rfs*74 | Q9Y2B0 | protein_coding | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
| CNPY2 | SNV | Missense_Mutation | rs755207888 | c.380N>T | p.Ser127Leu | p.S127L | Q9Y2B0 | protein_coding | deleterious(0.03) | benign(0.059) | TCGA-MY-A5BF-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
| CNPY2 | SNV | Missense_Mutation | c.113N>C | p.Leu38Pro | p.L38P | Q9Y2B0 | protein_coding | deleterious(0) | possibly_damaging(0.892) | TCGA-AA-3684-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| CNPY2 | SNV | Missense_Mutation | c.86N>A | p.Gly29Glu | p.G29E | Q9Y2B0 | protein_coding | deleterious(0.01) | probably_damaging(0.966) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| CNPY2 | SNV | Missense_Mutation | c.227C>T | p.Ala76Val | p.A76V | Q9Y2B0 | protein_coding | tolerated(0.27) | benign(0.039) | TCGA-AF-6655-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| CNPY2 | SNV | Missense_Mutation | c.453N>A | p.Phe151Leu | p.F151L | Q9Y2B0 | protein_coding | tolerated(0.93) | benign(0.017) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CNPY2 | SNV | Missense_Mutation | novel | c.505G>T | p.Asp169Tyr | p.D169Y | Q9Y2B0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |